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The impact of the introduction of bortezomib on 
dialysis independence in multiple myeloma patients
with renal impairment: a nationwide Dutch 
population-based study
The proteasome inhibitor bortezomib has a positive
effect on renal function in multiple myeloma (MM)
patients with renal impairment (RI).1-3 This led to an
update of the Dutch and international guidelines in 2010,
recommending bortezomib as first-line treatment in
patients with RI.1,4 Our results show that the number of
patients becoming dialysis independent increased more
than twofold and more rapidly in the first year of dialysis
treatment after the establishment of bortezomib as first-
line treatment in MM patients with RI. Age <75 years
and MM nephropathy without amyloidosis were associ-
ated with achieving dialysis independence.
RI in MM patients occurs in 20-50% of patients at diag-
nosis and is associated with poor survival.5-7
Approximately 10% of these patients require dialysis.8
Myeloma cast nephropathy (MCN) is the most common
type of renal injury in MM patients, other causes are
amyloid light chain amyloidosis (AL amyloidosis) or light
chain deposition disease (LCDD).9 Few studies evaluated
the effect of bortezomib in dialysis-dependent MM
patients.10,11 We determined the effect of the guideline
introducing bortezomib as first-line treatment in dialysis-
dependent MM patients on becoming dialysis independ-
ent. Online Supplementary Figure S1 highlights changes in
first-line treatment in the Netherlands.
We included patients on chronic renal replacement
therapy (RRT) (renal transplantation or dialysis treatment
>28 days) registered in the nationwide Dutch renal reg-
istry Renine between January 2002 and January 2016.
Patients are coded as MM nephropathy without proven
amyloidosis (MCN or LCDD) or as confirmed AL amyloi-
dosis. Every Dutch dialysis center is obliged to provide
data regarding age, gender, start date of RRT, type and
switches of RRT or hospitals, primary renal diagnosis,
date and cause of death.12 No information regarding
(chemo)therapy is provided. 
Patients were divided into two cohorts based on the
initial date of dialysis treatment: a pre-guideline cohort
(preGC)(January 1, 2002, until March 29, 2010) and post-
guideline cohort (postGC)(March 29, 2010, until January
1, 2016). For our primary analysis we considered only the
first change in renal status (dialysis independence, renal
transplantation, death, remaining dialysis dependent).
Additional changes were used for secondary analyses.  
Dialysis independence was defined as restoration of
renal function leading to dialysis independence for at
least two consecutive months.13 Restoration of renal
function as a result of renal transplantation was classified
as failure to achieve dialysis independence by the use of
bortezomib. For comparison purposes, maximum follow
up was limited to 4 years for each patient. 
The primary endpoint was dialysis independence,
depicted using the Kaplan-Meier method. Cox propor-
tional hazards modeling was used to assess pre- and
post-guideline differences. Adjusted hazard ratios
(HRadj.) with 95% confidence intervals (95%CI) were
estimated using a multivariable model. All indicators uni-
variately associated (P<0.10) with achieving dialysis inde-
pendence were considered for multivariable modeling. A
two-tailed P value <0.05 indicated statistical significance.
Analyses were performed using Statistical Analysis
System version 9.4 (SAS Institute, Cary, NC, USA).
During the study period, 710 patients were registered
in Renine. Ten patients were excluded due to immediate
renal transplantation (n=2) or loss of follow up after ini-
tial registration in Renine (n=8). The baseline characteris-
tics are presented in Table 1. The preGC and postGC
consisted of 422 and 278 patients, respectively. There
were no significant differences regarding gender, age,
type of dialysis, or primary renal disease between the
cohorts. 
As Figure 1 shows, 19% (n=43) of the patients became
dialysis independent in the postGC compared to 11%
(n=32) in the preGC within 4 years after starting dialysis
treatment. Median follow up in the preGC and postGC
was 1.3 years [95%CI 1.1-1.6] and 1.2 years [95%CI 0.9-
1.4], respectively. Dialysis independence was mainly
reached in the first year of dialysis treatment, during
which more patients became independent more rapidly
in the postGC. Within the first year, the postGC showed
a 2.3-fold increased chance of becoming dialysis inde-
pendent (HRadj.≤1year=2.3 [95%CI 1.5-4.0]), whereas
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Table 1. Baseline characteristics of the Dutch MM population on renal replacement therapy.
Total Pre-guideline Post-guideline P
(n = 700) (n = 422) (n = 278)
Male sex; n (%) 412 (59) 246 (58) 166 (60) 0.75
Mean age; years (SD) 66 (12) 65 (11) 66 (12) 0.44
Age; n (%) 0.28
< 65 289 (41) 180 (43) 109 (39)
65 – 75 256 (37) 157 (37) 99 (36)
≥ 75 155 (22) 85 (20) 70 (25)
Type of dialysis; n (%) 0.30
Hemodialyses 613 (88) 365 (86) 248 (89)
Peritoneal dialysis 87 (12) 57 (14) 30 (11)
Primary renal disease; n (%) 0.14
MM nephropathy 478 (68) 279 (66) 199 (72)
AL amyloidosis 222 (32) 143 (34) 79 (28)
P values indicate differences between the pre- and post-guideline cohort. MM: multiple myeloma; AL: amyloidosis: amyloid light chain amyloidosis. 
after 1 year such a difference was no longer present
(HRadj.>1year=0.83 [95%CI 0.16-4.4]). 
A substantial number of patients not reaching dialysis
independence deceased. Median overall survival (OS) of
patients on dialysis treatment was 1.32 years (95%CI
1.10-1.58) and 1.74 years (95%CI 1.39-2.21) for the
preGC and postGC, respectively (Online Supplementary
Figure S2). 
In addition to treatment period, multivariable model-
ing showed a significantly better outcome for patients
<75 years compared to the older patients (HRadj.=2.1
[95%CI 1.0-4.2], Table 2). There was no difference
between patients aged <65 and 65-75 years (HR=1.0
[95%CI 0.6-1.7]). Therefore, age was included as <75 vs.
≥75 years. Patients with MM nephropathy (MCN or
LCDD) were almost 6 times more likely to reach dialysis
independence than patients with AL amyloidosis
(HRadj.=5.7 [95%CI 2.5-13.2]). Gender and type of dial-
ysis were not significantly associated with achieving dial-
ysis independence. 
Of the 75 patients who became dialysis independent,
16 (21%) eventually resumed dialysis within 4 years. The
majority relapsed within 2 years. There was no signifi-
cant difference in relapse between the two cohorts
(HR=0.84 [95% CI 0.31-2.2]; Online Supplementary Figure
S3). 
This is one of the largest studies of MM patients with
dialysis dependency to date, encompassing all MM
patients on dialysis in the Netherlands over a period of 14
years. The number of patients becoming independent of
dialysis doubled after establishing bortezomib as first-
line treatment in MM patients with RI, independent of
other risk indicators. This difference was mainly
observed in the first year of dialysis treatment. 
Our study underlines the poor prognosis in the restora-
tion of renal function once a MM patient is dialysis
dependent. Loss of dialysis independence was not signif-
icantly different before or after 2010, indicating that the
improved probability of dialysis independence was not
caused by a higher risk of relapse but rather a sustained
response to therapy. In line with the OS of previous stud-
ies, OS of patients who remained on dialysis was poor in
both cohorts.10,11 As found by others,10 our study showed
that patients with MM nephropathy were almost 6 times
more likely to become dialysis independent than patients
with AL amyloidosis. This may be explained by the etiol-
ogy of AL amyloidosis, where fibrils are mainly deposited
in the glomeruli and soft tissues, as opposed to the pos-
sibly more reversible nature of MCN and LCDD where
no fibrils are formed. 
The improvement in dialysis independence after the
introduction of bortezomib was previously suggested in
France. Decourt et al.10 used the national database REIN
and after 2 years of follow up, 5% of the patients became
dialysis independent between 2002-2006 compared to
13% between 2006-2011. However, the coverage of
patients in this period was not 100%14 and selection bias
could have occurred. The lower percentages in the
French study could be explained as bortezomib was not
yet used as a first-line treatment in 2006 in France and
the exposure of bortezomib in our patients could there-
fore be higher and earlier in the course of the disease. In
addition, in a second French study,11 dialysis independen-
cy of 17% and 44% was observed after 2 years in the
preGC (1999-2008) and postGC (2008-2014), respective-
ly. However, this was a small, single-center study and
patients with AL amyloidosis were excluded. 
The major strength of our study is the compulsory
nature, quality, and completeness of the collected infor-
mation in Renine. The database provides a representa-
tive, population-based, and complete overview of dialy-
sis treatment in the Netherlands without selection bias
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Table 2. Hazard ratios for achieving Dialysis Independence within 4 years in univariate and multivariable analyses of MM patients.
Risk factors Univariate analysis Multivariable analysis
Crude HR (95% CI) P Adjusted HR (95% CI) P
Sex 0.533 -
Female 1
Male 1.2 (0.70 – 1.9)
Age 0.059 0.040
< 75 years 2.0 (0.97 – 3.9) 2.1 (1.0 – 4.2)
≥ 75 years 1 1
Primary renal disease < 0.001 < 0.001
AL amyloidosis 1 1
MM nephropathy 6.0 (2.6 – 13.8) 5.7 (2.5 – 13.2)
Type of dialysis 0.038 -
Peritoneal dialysis 1
Hemodialysis 2.9 (1.1 – 7.9)
Treatment*
Pre-guideline ≤ 1 year 1 < 0.001 1 < 0.001
Post-guideline ≤ 1 year 2.5 (1.5 – 4.0) 2.3 (1.4 – 3.7)
Pre-guideline > 1 year 1 0.949 1 0.826
Post-guideline >1 year 0.95 (0.18 – 5.0) 0.83 (0.16 – 4.4)
*Treatment according to the guideline analyzed as initial response within the first year of dialysis dependence versus the response after one year of dialysis dependence
(time dependent variable in Cox regression). MM: multiple myeloma, AL: amyloidosis: amyloid light chain amyloidosis. 
and with a long follow up. However, this study had some
limitations. Firstly, no detailed information about MM
disease history or treatment was recorded. Therefore, the
phase at which dialysis was needed or the use of borte-
zomib was unknown for individual cases. As bortezomib
was prescribed as second- and/or third-line treatment at
progression or relapse and was administered off-label as
induction therapy in MM patients with RI before 2010,
we speculate that the effect of bortezomib on renal
recovery is likely to be even more prominent than pre-
sented here. Furthermore, we recently showed that the
majority of MM patients with an eGFR below 15 ml/min
received a bortezomib-based treatment as first-line treat-
ment in the last decade.15 Secondly, renal biopsies were
only routinely performed to confirm AL amyloidosis. The
exact etiology of nephropathy due to MM may be
unknown and could induce bias. Thirdly, improved care
could have influenced the increase of achieving dialysis
independence. Although unknown for patients in the
Netherlands, Decourt et al. showed that control patients
on dialysis without MM did not show an improvement
in renal recovery before or after 2006.10  
As illustrated by the poor OS, further steps are neces-
sary to improve outcomes in patients on dialysis treat-
ment. Our results showed that especially in the first year
of dialysis treatment, restoration of renal function can be
achieved. Therefore, a close interaction between
nephrologists and haematologists in the diagnostic
process, rapid initiation of more intensive therapy
schemes comprising additional antimyeloma agents, and
closer adherence to guidelines may be effective strategies
to optimize outcomes in these patients.
In conclusion, our study showed an increase in the
number of patients becoming independent of dialysis
after the establishment of bortezomib as first-line treat-
ment of MM patients with RI. This effect arises predom-
inantly in the first year of dialysis treatment. Age <75
years and MCN/LCDD as primary renal disease were
associated with achieving dialysis independence.
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